Welcome to our dedicated page for Viaderma news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on Viaderma stock.
ViaDerma, Inc. (VDRM) is a biotechnology innovator advancing transdermal drug delivery systems and topical pharmaceutical solutions. This page serves as the definitive source for ViaDerma-related news, providing investors and industry observers with timely updates on corporate developments, regulatory milestones, and market expansion activities.
Visitors will find comprehensive coverage of ViaDerma's strategic initiatives, including new product launches, licensing agreements, and research advancements in wound care and pain management. The curated news collection enables stakeholders to track the company's progress in addressing global healthcare challenges through its proprietary drug delivery platforms.
Key updates include earnings announcements, partnership disclosures, and international regulatory approvals that underscore ViaDerma's position in specialty pharmaceuticals. All content is verified for accuracy and relevance to maintain its value as a long-term reference.
Bookmark this page to stay informed about ViaDerma's innovations in transdermal technology and its expanding presence across emerging markets. Check back regularly for objective reporting on operational achievements that shape the company's trajectory in biotechnology.
ViaDerma, Inc. (VDRM) announced plans to launch a new hair regrowth product using Minoxidil with a proprietary transdermal delivery technology. This technology enhances absorption, significantly outperforming traditional treatments. The global hair restoration market is projected to reach $13.6 billion by 2028, while the Minoxidil market is expected to grow to $1.43 billion during the same time frame. FDA registration for the product is anticipated within 90 days, aiming for market availability later this year. CEO Dr. Chris Otiko expressed excitement about entering this expanding industry.
ViaDerma, Inc. (OTC Pink: VDRM) has expanded its licensing agreement with a major wound care network to 11 states, aiming for nationwide coverage within 12 months. This expansion increases monthly royalties from $50,000 to $55,000. The company has also launched a new website, ViaDerma.com, to enhance brand recognition and customer engagement. Additionally, ViaDerma is pursuing insurance coverage for its products, Vitastem and Vitastem Ultra, which are eligible for OTC benefits. President & CEO Dr. Chris Otiko noted recovery from previous supply chain issues, with optimistic sales forecasts for 2023.
ViaDerma, Inc. (OTC Pink: VDRM) has engaged INTENT SCIENCES to enhance its online brand and marketing efforts in 2023. The partnership aims to leverage INTENT SCIENCES' expertise in digital marketing to grow demand for ViaDerma's flagship product, Vitastem Ultra, which addresses various skin ailments. With over 35 million monthly searches for related conditions, this collaboration focuses on improving search visibility and increasing revenues. ViaDerma is also pursuing several large purchase orders, signaling confidence in future growth.
ViaDerma, Inc. (OTC Pink: VDRM) announced the successful completion of internal quality control testing for its new Vitastem products, allowing the company to resume online sales. The new formulations, Vitastem and Vitastem Ultra, are FDA-registered topical antibiotics effective against various bacteria associated with skin conditions. The CEO, Dr. Chris Otiko, expressed confidence in moving forward with sales and potential purchase orders. The company plans to file its second-quarter financial report soon, resolving delays due to missing information.
ViaDerma (OTC Pink: VDRM) has announced that large-scale production of its new Vitastem products is underway and additional internal quality control testing will be conducted. The company aims to ensure optimal performance of these FDA-registered topical antibiotics, which utilize new formulations. The upgraded products, Vitastem and Vitastem Ultra, offer enhanced efficacy against harmful bacteria and provide alternatives for consumers with ingredient sensitivities. Completion of the testing is expected within four weeks, with distribution commencing shortly thereafter.
ViaDerma, Inc. (VDRM) reported a staggering 4382% revenue increase in 2021, totaling $514,007 compared to $11,468 in 2020. Gross profits surged by 4621%, rising from $10,831 to $511,335. The company also improved its asset figures, with total assets rising by 123% to $275,021. Furthermore, total liabilities decreased by over 25%, from $3,631,096 to $2,710,201. CEO Dr. Chris Otiko acknowledged the challenges posed by COVID-19 but expressed optimism for resumed production and sales of Vitastem.
ViaDerma, Inc. (OTC Pink: VDRM) announces the launch of enhanced formulas for its popular products, Vitastem and Vitastem Ultra. The original Vitastem, a strong topical antibiotic, now features a clear, non-staining formula, making it user-friendly. Vitastem Ultra, with bacitracin as its active ingredient, offers an alternative for those allergic to tetracycline or dealing with resistant bacteria. Both products are set to be available by mid-October through Amazon and other retailers. The previous versions will be phased out as the new products are introduced.
ViaDerma, Inc. (OTC Pink: VDRM) reported on August 24, 2021, a quarterly financial review revealing Convertible Notes Payable of $281,538 and a Convertible Line of Credit totaling $19,000. An internal audit disclosed that outstanding convertible debt was actually $300,358, contradicting a previous statement about settling these liabilities. Additionally, VDRM identified an unrecorded liability of $200,000. The company is preparing to receive funds from a recent Dubai transaction, which will facilitate a financial audit, a crucial step toward potential OTCQB listing.
ViaDerma, Inc. (OTC Pink: VDRM) has finalized a ten-year licensing agreement worth $12 million with a company in Dubai, granting exclusive rights to sell its products in the Middle East. The first payment of $600,000 is expected by August 5, 2021. Additionally, ViaDerma's partnership with a home health wound care network has expanded across nine states, generating $45,000 monthly in royalties. The company plans to hire an auditing firm within 30 to 60 days for financial audits necessary for an OTCQB listing application later this year.
ViaDerma, Inc. (OTC: VDRM) has expanded its licensing agreement with a home health wound care network, increasing monthly royalties from $35,000 to $40,000 due to the addition of two states. Expected revenue could reach $80,000 monthly by year-end. The company is also set to generate approximately $600,000 annually from a new limb salvage campaign. Additionally, President Dr. Chris Otiko will finalize a $12 million licensing agreement in Dubai by June 25, with an initial payment of $600,000 due upon conclusion.